SCHEMBL785089

SCHEMBL785089

CC(C)NC1CCc2cc(F)c(C(=O)O)cc21

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.37
SCN3A Q9NY46 1/20 0.36
SRD5A2 P31213 1/20 0.35
DPP4 P27487 3/20 0.34
MAPT P10636 1/20 0.34
KDM4C Q9H3R0 2/20 0.34
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A2 P05177 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL785977 0.94 ACHE (0.37) ACHESCN3ASRD5A2DPP4MAPT
SCHEMBL803164 0.86 SCN3A (0.37) ACHESCN3AMAPTCA12CA1
SCHEMBL803166 0.81 SCN3A (0.37) ACHESCN3AMAPTKDM4CCA12
SCHEMBL17269813 0.76 KDM4E (0.39) SRD5A2MAPTKDM4CKDM4ESMN1; SMN2
SCHEMBL784272 0.76 ALDH1A1 (0.45) ACHECYP1A2DRD3
SCHEMBL785710 0.73 ACHE (0.40) ACHEKDM4ESMN1; SMN2CYP1A2
SCHEMBL878395 0.73 ACHE (0.40) ACHEKDM4ESMN1; SMN2CYP1A2
Hydrochloric Acid SCHEMBL785812 0.72 ACHE (0.42) ACHEKDM4ESMN1; SMN2CYP1A2
Hydrochloric Acid SCHEMBL785811 0.72 ACHE (0.42) ACHEKDM4ESMN1; SMN2CYP1A2
SCHEMBL484460 0.71 ALDH1A1 (0.57) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 ACHE 746/4885SCN3A 928/4885SRD5A2 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.